ONCOHIGH SIGNALFINANCIAL10-K

ONCO executed a 1:85 reverse stock split and dramatically improved its cash position from $1.9M to $25.8M while pursuing a major transaction with Realbotix, LLC.

The extreme reverse stock split ratio (1:85) combined with the massive cash increase suggests emergency dilutive financing to avoid bankruptcy or delisting. The company appears to be pivoting away from its core business toward a robotics transaction, indicating potential distress in the underlying operations.

Comparing 2026-03-13 vs 2025-06-02View on EDGAR →
FINANCIAL ANALYSIS

ONCO's financial profile shows classic signs of a struggling company attempting a turnaround - cash surged 1,235% likely from emergency equity raises, while revenue collapsed 68% and R&D spending was slashed 92%. Despite the cash infusion improving stockholders' equity from negative $5.6M to positive $8.5M, the dramatic reduction in core business investment and revenue suggests the company may be abandoning its original business model. The financial changes reflect a company in survival mode rather than growth mode.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+1235.4%
$1.9M→$25.8M

Cash position surged 1235.4% — strong cash generation or capital raise providing significant financial cushion.

Accounts Receivable
Balance Sheet
+1054.4%
$26K→$297K

Receivables surged 1054.4% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Capital Expenditure
Cash Flow
+762.8%
$3K→$28K

Capital expenditure jumped 762.8% — major investment cycle underway; assess returns on deployment.

Current Assets
Balance Sheet
+538.4%
$950K→$6.1M

Current assets grew 538.4% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+252.5%
-$5.6M→$8.5M

Equity base grew 252.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Inventory
Balance Sheet
+134%
$64K→$150K

Inventory surged 134% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

R&D Expense
P&L
-92.1%
$1.9M→$154K

R&D spending cut 92.1% — could signal cost discipline or concerning reduction in innovation investment.

Net Income
P&L
+76.1%
-$58.7M→-$14.0M

Net income grew 76.1% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+68.4%
-$56.5M→-$17.9M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Revenue
P&L
-67.7%
$2.5M→$815K

Revenue declined 67.7% — significant demand weakness or market share loss warrants investigation.

LANGUAGE CHANGES
NEW — 2026-03-13
PRIOR — 2025-06-02
ADDED
As of March 11, 2026, the registrant had 3,584,245 shares of common stock, $0.00001 par value per share, outstanding.
EXPLANATORY NOTE On June 13, 2025, the Company effected a reverse stock split of all shares of its issued and outstanding Common Stock at a ratio of one-for-eighty-five (1:85).
All issued and outstanding common stock, common stock warrants, and share-based awards exercise prices and per share data have been adjusted in these consolidated financial statements, on a retrospective basis, to reflect the reverse stock split for all periods presented.
our ability to consummate the transaction on a timely basis as contemplated by the Share Exchange Agreement with Realbotix, LLC ( Realbotix and the Share Exchange Agreement and the transactions contemplated therein, the Realbotix Transaction ) and the anticipated benefits of the Realbotix Transaction.
These risks include, but are not limited to, the following: We could fail to complete the Realbotix Transaction, or the Realbotix Transaction may be completed on different terms.
+7 more — sign up free →
REMOVED
As of May 30, 2025, the registrant had 44,358,422 shares of common stock, $0.00001 par value per share, outstanding.
EXPLANATORY NOTE On September 24, 2024, the Company effected a Reverse Stock Split of all shares of its issued and outstanding Common Stock at a ratio of one-for-forty (1:40).
All issued and outstanding common stock, common stock warrants, and share-based awards exercise prices and per share data in this report and the consolidated financial statements have been adjusted, on a retrospective basis, to reflect the reverse stock split for all periods presented.
These risks include, but are not limited to, the following: Company shareholders may not realize a benefit from the ENTADFI or Proteomedix ( Proteomedix ) acquisitions commensurate with the ownership dilution they have experienced in connection with the transactions.
We may consider strategic alternatives in order to maximize stockholder value, including financing, strategic alliances, licensing arrangements, acquisitions or the possible sale of our business.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →